These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9048541)

  • 21. Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
    Wang YF; Tie Y; Boross PI; Tozser J; Ghosh AK; Harrison RW; Weber IT
    J Med Chem; 2007 Sep; 50(18):4509-15. PubMed ID: 17696515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
    Hodge CN; Aldrich PE; Bacheler LT; Chang CH; Eyermann CJ; Garber S; Grubb M; Jackson DA; Jadhav PK; Korant B; Lam PY; Maurin MB; Meek JL; Otto MJ; Rayner MM; Reid C; Sharpe TR; Shum L; Winslow DL; Erickson-Viitanen S
    Chem Biol; 1996 Apr; 3(4):301-14. PubMed ID: 8807858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
    Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
    FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease.
    Garg R; Bhhatarai B
    J Comput Aided Mol Des; 2008 Oct; 22(10):737-45. PubMed ID: 18368496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.
    Nugiel DA; Jacobs K; Kaltenbach RF; Worley T; Patel M; Meyer DT; Jadhav PK; De Lucca GV; Smyser TE; Klabe RM; Bacheler LT; Rayner MM; Seitz SP
    J Med Chem; 1996 May; 39(11):2156-69. PubMed ID: 8667359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
    Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
    Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
    Kar P; Lipowsky R; Knecht V
    J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
    Tie Y; Kovalevsky AY; Boross P; Wang YF; Ghosh AK; Tozser J; Harrison RW; Weber IT
    Proteins; 2007 Apr; 67(1):232-42. PubMed ID: 17243183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
    Mahalingam B; Louis JM; Hung J; Harrison RW; Weber IT
    Proteins; 2001 Jun; 43(4):455-64. PubMed ID: 11340661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
    Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
    J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
    Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
    J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
    Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
    J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.
    Mahalingam B; Louis JM; Reed CC; Adomat JM; Krouse J; Wang YF; Harrison RW; Weber IT
    Eur J Biochem; 1999 Jul; 263(1):238-45. PubMed ID: 10429209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
    Klei HE; Kish K; Lin PF; Guo Q; Friborg J; Rose RE; Zhang Y; Goldfarb V; Langley DR; Wittekind M; Sheriff S
    J Virol; 2007 Sep; 81(17):9525-35. PubMed ID: 17537865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.
    Lockbaum GJ; Leidner F; Rusere LN; Henes M; Kosovrasti K; Nachum GS; Nalivaika EA; Ali A; Yilmaz NK; Schiffer CA
    ACS Infect Dis; 2019 Feb; 5(2):316-325. PubMed ID: 30543749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
    Velazquez-Campoy A; Kiso Y; Freire E
    Arch Biochem Biophys; 2001 Jun; 390(2):169-75. PubMed ID: 11396919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.